Literature DB >> 9502079

Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro.

H Li1, H Shimura, Y Aoki, K Date, K Matsumoto, T Nakamura, M Tanaka.   

Abstract

Human gallbladder cancer is highly malignant and its prognosis is usually poor depending on the extent of surrounding tissue invasion. We examined in vitro the invasive activity of four gallbladder cancer cell lines (GB-d1, GB-h3, GB-d2 and FU-GBC-1) in the absence or presence of hepatocyte growth factor (HGF). In type 1 collagen gel culture, HGF stimulated cell proliferation and induced an invasive phenotype of arborizing structures in GB-d1, GB-h3 and GB-d2. In a Matrigel invasion assay, invasion was also induced in three of these cell lines by HGF but not in FU-GBC-1. Cellular motility was, however, stimulated by HGF in all of the four cell lines to various extents. Zymography for proteolytic enzymes demonstrated high levels of type IV collagenase and urokinase-type plasminogen activator (u-PA) activity in GB-d1, GB-h3 and GB-d2 even in the absence of HGF. In the presence of HGF, the 72 kDa type IV collagenase (MMP-2) activity of GB-h3 and u-PA activities of GB-d1, GB-h3 and GB-d2 were enhanced. In contrast, the MMPs and PAs activities of FU-GBC-1 were faint irrespective of the addition of HGF. A Western blot analysis demonstrated higher levels of 190 kDa c-MET product (HGF receptor) of GB-d1, GB-h3 and GB-d2 than that of FU-GBC-1. The invasion in the Matrigel assay stimulated by HGF was inhibited by protease inhibitors, aprotinin and FOY-305, as well as by anti-HGF antibody. These results thus suggest that, in addition to the importance of the proteolytic activity, the cellular motility induced via the HGF/HGF-receptor system is essential for the invasive progression of gallbladder carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502079     DOI: 10.1023/a:1006516119518

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  39 in total

1.  Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.

Authors:  J F Cajot; B Sordat; E K Kruithof; F Bachmann
Journal:  J Natl Cancer Inst       Date:  1986-09       Impact factor: 13.506

2.  Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix.

Authors:  T Furukawa; T Kubota; M Watanabe; S Kase; Y Saikawa; H Nishibori; T H Kuo; S Kodaira; K Ishibiki; M Kitajima
Journal:  J Surg Oncol       Date:  1992-02       Impact factor: 3.454

3.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 4.  Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.

Authors:  J S Rao; P A Steck; P Tofilon; D Boyd; F Ali-Osman; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Plasminogen activator profiles in neoplastic tissues of the human colon.

Authors:  P A de Bruin; G Griffioen; H W Verspaget; J H Verheijen; G Dooijewaard; H F van den Ingh; C B Lamers
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

6.  Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.

Authors:  C F Sier; H W Verspaget; G Griffioen; J H Verheijen; P H Quax; G Dooijewaard; P A De Bruin; C B Lamers
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

7.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

Authors:  C F Sier; H W Verspaget; G Griffioen; S Ganesh; H J Vloedgraven; C B Lamers
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

Review 8.  Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis.

Authors:  W G Jiang; M B Hallett; M C Puntis
Journal:  Br J Surg       Date:  1993-11       Impact factor: 6.939

9.  Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells.

Authors:  H Sato; Y Kida; M Mai; Y Endo; T Sasaki; J Tanaka; M Seiki
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein.

Authors:  N Shima; M Nagao; F Ogaki; E Tsuda; A Murakami; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1991-10-31       Impact factor: 3.575

View more
  10 in total

1.  Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.

Authors:  K Murakami; R Sakukawa; T Ikeda; T Matsuura; S Hasumura; S Nagamori; Y Yamada; I Saiki
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

3.  Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.

Authors:  T Moriyama; H Kataoka; R Hamasuna; E Yoshida; T Sameshima; T Iseda; K Yokogami; S Nakano; M Koono; S Wakisaka
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

4.  Identification of novel cellular targets in biliary tract cancers using global gene expression technology.

Authors:  Donna E Hansel; Ayman Rahman; Manuel Hidalgo; Paul J Thuluvath; Keith D Lillemoe; Richard Schulick; Ja-Lok Ku; Jae-Gahb Park; Kohje Miyazaki; Raheela Ashfaq; Ignacio I Wistuba; Ram Varma; Lesleyann Hawthorne; Joseph Geradts; Pedram Argani; Anirban Maitra
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

5.  Protection of trocar sites from gallbladder cancer implantation by sodium hyaluronate carboxymethylcellulose-based bioresorbable membrane (Seprafilm) in a murine model [corrected].

Authors:  T Sasaki; H Shimura; T Tanaka; K Nakashima; K Matsuo; S Ikeda
Journal:  Surg Endosc       Date:  2003-12-29       Impact factor: 4.584

6.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.

Authors:  Shinya Mizuno; Toshikazu Nakamura
Journal:  Int J Mol Sci       Date:  2013-01-07       Impact factor: 5.923

Review 8.  Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge.

Authors:  Wasia Rizwani; Amanda E Allen; Jose G Trevino
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

Review 9.  Targeting HGF/c-MET Axis in Pancreatic Cancer.

Authors:  Srinivasa P Pothula; Zhihong Xu; David Goldstein; Romano C Pirola; Jeremy S Wilson; Minoti V Apte
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 10.  Overview of current targeted therapy in gallbladder cancer.

Authors:  Xiaoling Song; Yunping Hu; Yongsheng Li; Rong Shao; Fatao Liu; Yingbin Liu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.